In the present study, we have provided sufficient evidence to demonstrate for the first time that TRPV1 is a Ca2+-permeable channel that uniquely suppresses GC development through activation of a novel CaMKKβ/AMPK pathway. The gene discussed is CA2; the disease is gastric cancer.